March 25, 2003. It is the policy of the National Institute of Health that women and members of minority groups must be included in all NIH supported biomedical and behavioral research projects.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA on Artecoll
February 28, 2003. If FDA approval is to mean anything, it should mean that the benefits outweigh the risks. The benefits are purely cosmetic, and most are not statistically-significant. We don’t know exactly what the risks are yet.
Read More »NCHR President Testimony at FDA on Artecoll
February 28, 2003. As an epidemiologist, if asked if Artecoll is a safe product, based on the data that you’re going to be hearing today, I would have to respond it depends on what you mean by “safe.”
Read More »